Patents by Inventor Atsushi Kimbara

Atsushi Kimbara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20190248803
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Olivier GAVELLE, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Pyridine derivatives
    Patent number: 10308659
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier Gavelle, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Roever Stephan, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Pyrazol derivatives
    Patent number: 9694012
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Triazolo[4,5-D]pyrimidine derivatives
    Patent number: 9593123
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 14, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Stephan Roever, Sebastien Schmitt, Atsushi Kimbara
  • Pyrrolo[2,3-D]pyrimidine derivatives as CB2 receptor agonists
    Patent number: 9580435
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: February 28, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20170035769
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, MATTHIAS NETTEKOVEN, FABIENNE RICKLIN, STEPHAN ROEVER, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • Pyridine derivatives
    Patent number: 9522886
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: December 20, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Pyrazole compounds as CB2 agonists
    Patent number: 9512132
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 6, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Nettekoven Matthias, Ricklin Fabienne, Roever Stephan, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Purine derivatives as CB2 receptor agonists
    Patent number: 9505762
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: November 29, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
    Patent number: 9499553
    Abstract: The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 22, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Yoshihito Ohtake, Naoki Okamoto, Yoshiyuki Ono, Hirotaka Kashiwagi, Atsushi Kimbara, Takeo Harada, Nobuyuki Hori, Yoshihisa Murata, Kazutaka Tachibana, Shota Tanaka, Kenichi Nomura, Mitsuaki Ide, Eisaku Mizuguchi, Yasuhiro Ichida, Shuichi Ohtomo, Naoshi Horiba
  • Pyridine-2-amides useful as CB2 agonists
    Patent number: 9409866
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 9, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch, Matthias Westphal
  • NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
    Publication number: 20160168158
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Stephan Roever, Sebastien Schmitt, Atsushi Kimbara
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160137606
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9321727
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Pyridine-2-amides useful as CB2 agonists
    Patent number: 9303012
    Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 5, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Ernst Schaffter, Tanja Schulz-Gasch
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9290451
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046631
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046637
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160016968
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 28, 2015
    Publication date: January 21, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier GAVELLE, Uwe GRETHER, Atsushi KIMBARA, Nettekoven MATTHIAS, Roever STEPHAN, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH
  • DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
    Publication number: 20160002251
    Abstract: The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.
    Type: Application
    Filed: September 14, 2015
    Publication date: January 7, 2016
    Inventors: Yoshihito OHTAKE, Naoki OKAMOTO, Yoshiyuki ONO, Hirotaka KASHIWAGI, Atsushi KIMBARA, Takeo HARADA, Nobuyuki HORI, Yoshihisa MURATA, Kazutaka TACHIBANA, Shota TANAKA, Kenichi NOMURA, Mitsuaki IDE, Eisaku MIZUGUCHI, Yasuhiro ICHIDA, Shuichi OHTOMO, Naoshi HORIBA